What are Neutrophil elastase inhibitor drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neutrophil elastase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Neutrophil elastase (NE)). 0 are currently marketed, with 2 more in clinical development.

Neutrophil elastase inhibitor

0 marketed 1 in Phase 3 1 in Phase 2

This page covers all Neutrophil elastase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Neutrophil elastase (NE), Neutrophil elastase.

Targets

Neutrophil elastase (NE) · Neutrophil elastase

Phase 3 pipeline (1)

NRL972 · Norgine · Respiratory / Pulmonology
NRL972 is a selective inhibitor of neutrophil elastase that reduces protease-mediated tissue damage in inflammatory airway diseases.

Phase 2 pipeline (1)

Alvelestat oral tablet - dose 1 · Mereo BioPharma · Respiratory
Alvelestat is a selective inhibitor of neutrophil elastase, an enzyme involved in the degradation of lung tissue.

Patent intelligence

neutrophil elastase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates